About Genovis

The Genovis Group consists of Genovis AB, Sweden, and the wholly owned subsidiary Genovis Inc., USA. The company has aprox. 2,600 shareholders and the company's shares are listed on Nasdaq First North Growth Market. Find more information at  Investor Relations.

 

Genovis’ business concept is to offer customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Genovis enzyme products, known as SmartEnzymes, are used by scientists all over the world and the innovative product formats facilitate development and quality control of biological drugs.

 Through the acquisition of QED Bioscience in 2020 the product portfolio has expanded to include antibodies and reagents for use in research, biological drug development and diagnostic assays. Read more about QED at www.qedbio.com

A cornerstone of Genovis’ R&D activities is customer relations that enables product development to meet customer needs. Just as valuable is the collaboration with academic groups that focus on characterizing new enzymes, developing new workflows and antibodies for novel targets.

Order